Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Research helps explain how vedolizumab antibody therapy leads to sustained viral remission

HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection,

Published
23 March 2017
By
Liz Highleyman
Several new candidates in HIV drug pipeline discussed at conference

This year's Conference on Retroviruses and Opportunistic Infections (CROI 2017), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more

Published
15 March 2017
By
Liz Highleyman
New antibody therapy “profoundly” successful at reducing inflammation from HIV

In a very small study of people living with HIV, a one-time antibody treatment significantly reduced the type of inflammation that can lead to heart attacks and other cardiovascular problems.

Published
09 March 2017
From
BETA blog
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good

Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard three-drug combination regimen, according to research

Published
09 March 2017
By
Liz Highleyman
Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

TAF containing products can be made available to patients who have defined renal or bone problems or who have medical reasons why they cannot take other HIV drugs.

Published
06 March 2017
From
NHS England
New HIV capsid inhibitors show high potency and prolonged activity in early studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer

Published
03 March 2017
By
Liz Highleyman
Monoclonal antibodies show promise for HIV-positive people with limited treatment options

A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells – ibalizumab and PRO 140 – may offer new treatment options for people with

Published
22 February 2017
By
Liz Highleyman
New nano approach could cut dose of leading HIV treatment in half

Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

Published
21 February 2017
From
University of Liverpool press release
Merck's lead HIV play hits the mark in first phase 3 challenge

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a showdown with Johnson & Johnson's big-selling Prezista.

Published
19 February 2017
From
FierceBiotech
New NNRTI doravirine shows good efficacy in phase 3 study

Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a phase 3 clinical trial of

Published
19 February 2017
By
Liz Highleyman
← First12345...95Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.